INmune Bio (NASDAQ:INMB) Announces Earnings Results

INmune Bio (NASDAQ:INMB) posted its earnings results on Thursday. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.14, Zacks reports.

INmune Bio Stock Performance

Shares of NASDAQ INMB opened at $7.52 on Friday. The company’s 50 day moving average price is $8.41 and its 200-day moving average price is $6.38. INmune Bio has a 52-week low of $4.32 and a 52-week high of $12.72. The company has a market capitalization of $199.96 million, a P/E ratio of -3.45 and a beta of 1.93.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on INMB. Rodman & Renshaw initiated coverage on INmune Bio in a research note on Tuesday, January 28th. They issued a “buy” rating and a $23.00 price objective for the company. RODMAN&RENSHAW raised shares of INmune Bio to a “strong-buy” rating in a report on Tuesday, January 28th. Maxim Group raised their price target on shares of INmune Bio from $22.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. Finally, Scotiabank boosted their price objective on shares of INmune Bio from $22.00 to $23.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, February 11th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, INmune Bio has a consensus rating of “Buy” and a consensus price target of $22.80.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.